All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
FDA approves idecabtagene vicleucel for triple-class-exposed RRMM
Bookmark this article
On April 5, 2024, the U.S. Food and Drug Administration granted approval to idecabtagene vicleucel (ide-cel) for the treatment of triple-class-exposed relapsed/refractory multiple myeloma (RRMM) after two or more prior therapies, including an immunomodulatory agent (IMiD), proteasome inhibitor (PI), and an anti-CD38 antibody.1
This approval was based on data from the phase III KarMMa-3 (NCT03651128) clinical trial.1 The Multiple Myeloma Hub has previously reported on the trial design of KarMMa-3 here.
KarMMa-3 pivotal data1
- A total of 254 patients were randomized for treatment with ide-cel and 132 to a comparator arm consisting of standard regimens.
- At a median follow up of 15.9 months:
- Median progression-free survival (PFS) was significantly higher in the ide-cel arm at 13.3 months vs 4.4 months in the control arm.
- An overall response rate of 71% was observed with ide-cel, and a complete or stringent complete response rate of 39%.
- Median duration of overall response was 14.8 months in the ide-cel arm, and duration of complete/better response was 20 months.
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy. https://www.businesswire.com/news/home/20240403030392/en/U.S.-FDA-Approves-Bristol-Myers-Squibb-and-2seventy-bio%E2%80%99s-Abecma-for-Triple-Class-Exposed-Relapsed-or-Refractory-Multiple-Myeloma-After-Two-Prior-Lines-of-Therapy. Published Apr 5, 2024. Accessed Apr 8, 2024.
Your opinion matters
70 votes - 41 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox